Abstract
Structure-based drug design methods were used to search for novel inhibitors of herpes simplex virus type 1 (HSV-1) thymidine kinase and Mycobacterium tuberculosis thymidylate kinase. The method involved the use of crystal structure complexes to guide database searching for potential inhibitors. A number of weak inhibitors of HSV-2 were identified, one of which was found to inhibit HSV-1 TK and HSV-1 TK-deficient viral strains. Each compound tested against M. tuberculosis thymidylate kinase was found to have some activity. The best of these compounds was only 4.6-fold less potent than 3'-azido-3'-deoxythymidine-5'-monophosphate (AZTMP). This study demonstrates the utility of structure-based drug design methods in the search for novel enzyme inhibitors.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Bacterial Agents
-
Anti-Infective Agents / chemistry
-
Anti-Infective Agents / pharmacology
-
Anti-Infective Agents / toxicity
-
Binding Sites
-
Cell Line
-
Databases, Factual*
-
Drug Design
-
Enzyme Inhibitors / chemistry*
-
Enzyme Inhibitors / pharmacology
-
Enzyme Inhibitors / toxicity
-
Herpesvirus 1, Human / enzymology
-
Herpesvirus 2, Human / enzymology
-
Humans
-
Microbial Sensitivity Tests
-
Molecular Structure
-
Mycobacterium tuberculosis / enzymology
-
Nucleoside-Phosphate Kinase / antagonists & inhibitors*
-
Structure-Activity Relationship
-
Thymidine Kinase / antagonists & inhibitors*
Substances
-
Anti-Bacterial Agents
-
Anti-Infective Agents
-
Enzyme Inhibitors
-
Thymidine Kinase
-
Nucleoside-Phosphate Kinase
-
dTMP kinase